Taysha Gene Therapies Quarterly Balance Sheets Chart
Quarterly
|
Annual
Taysha Gene Therapies Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||
| current assets: | ||||||||||||||||||||
| cash and cash equivalents | 312,761,000 | 116,593,000 | 139,036,000 | 157,688,000 | 172,743,000 | 123,980,000 | 143,940,000 | 164,278,000 | 45,083,000 | 63,425,000 | 87,880,000 | 34,306,000 | 66,239,000 | 96,630,000 | 149,103,000 | 188,785,000 | 197,370,000 | 228,684,000 | 251,253,000 | 278,634,000 |
| restricted cash | 449,000 | 449,000 | 449,000 | 449,000 | 449,000 | 449,000 | 449,000 | 2,637,000 | 2,637,000 | 2,637,000 | 2,637,000 | 2,637,000 | 2,637,000 | 2,637,000 | 2,637,000 | 2,628,000 | ||||
| prepaid expenses and other current assets | 3,054,000 | 3,666,000 | 2,645,000 | 3,418,000 | 3,278,000 | 4,168,000 | 3,479,000 | 5,529,000 | 9,032,000 | 8,933,000 | 8,537,000 | 8,696,000 | 10,596,000 | 10,261,000 | 10,499,000 | 8,385,000 | 9,932,000 | 10,817,000 | 6,626,000 | |
| total current assets | 316,264,000 | 120,708,000 | 142,130,000 | 161,555,000 | 178,470,000 | 130,597,000 | 149,868,000 | 171,807,000 | 54,115,000 | 72,358,000 | 96,417,000 | 43,002,000 | 76,835,000 | 106,891,000 | 159,602,000 | 197,170,000 | 207,302,000 | 239,629,000 | 257,879,000 | 279,238,000 |
| property, plant and equipment | 6,957,000 | 7,236,000 | 7,485,000 | 7,613,000 | 10,513,000 | 10,686,000 | 10,826,000 | 11,169,000 | 14,139,000 | 14,642,000 | 14,963,000 | 63,954,000 | 61,011,000 | 55,120,000 | 50,610,000 | 40,553,000 | 33,867,000 | 2,497,000 | ||
| operating lease right-of-use assets | 7,773,000 | 8,079,000 | 8,381,000 | 8,678,000 | 8,971,000 | 9,261,000 | 9,582,000 | 9,852,000 | 10,348,000 | 10,647,000 | 10,943,000 | |||||||||
| other non-current assets | 186,000 | 188,000 | 217,000 | 220,000 | 288,000 | 304,000 | 304,000 | 304,000 | 304,000 | 1,316,000 | 1,316,000 | 1,245,000 | 1,206,000 | 673,000 | 440,000 | |||||
| total assets | 333,331,000 | 138,362,000 | 160,364,000 | 180,217,000 | 200,393,000 | 152,999,000 | 172,731,000 | 195,769,000 | 81,543,000 | 101,600,000 | 126,276,000 | 111,468,000 | 142,332,000 | 165,976,000 | 213,956,000 | 241,042,000 | 241,860,000 | 242,829,000 | 258,881,000 | 279,266,000 |
| liabilities and stockholders' equity | ||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||
| accounts payable | 7,713,000 | 4,326,000 | 3,592,000 | 4,932,000 | 8,718,000 | 10,380,000 | 6,366,000 | 7,520,000 | 10,766,000 | 9,002,000 | 10,946,000 | 15,251,000 | 23,967,000 | 21,997,000 | 21,763,000 | 22,051,000 | 6,355,000 | 4,083,000 | 1,994,000 | 8,837,000 |
| accrued expenses and other current liabilities | 12,151,000 | 10,761,000 | 12,862,000 | 12,608,000 | 11,875,000 | 13,562,000 | 12,284,000 | 13,638,000 | 19,632,000 | 16,602,000 | 18,287,000 | 17,888,000 | 18,986,000 | 26,620,000 | 29,983,000 | 21,163,000 | 22,036,000 | 14,875,000 | 5,135,000 | |
| deferred revenue | 5,485,000 | 7,470,000 | 9,773,000 | 11,795,000 | 13,583,000 | 14,695,000 | 18,106,000 | 18,759,000 | 20,243,000 | 28,851,000 | 33,557,000 | |||||||||
| total current liabilities | 25,349,000 | 22,557,000 | 26,227,000 | 29,335,000 | 34,176,000 | 38,637,000 | 36,756,000 | 180,451,000 | 50,641,000 | 54,455,000 | 62,790,000 | 33,139,000 | 42,953,000 | 48,617,000 | 51,746,000 | 43,214,000 | 28,391,000 | 18,958,000 | 7,129,000 | 11,624,000 |
| term loan | 41,051,000 | 42,453,000 | 43,942,000 | 42,971,000 | 37,835,000 | 40,512,000 | 40,508,000 | 38,548,000 | 38,354,000 | 38,161,000 | 37,967,000 | 37,773,000 | 37,580,000 | 37,386,000 | 37,192,000 | 27,812,000 | ||||
| operating lease liability, net of current portion | 16,808,000 | 17,093,000 | 17,361,000 | 17,751,000 | 18,134,000 | 18,499,000 | 18,953,000 | 19,101,000 | 19,528,000 | 19,928,000 | 20,440,000 | |||||||||
| other non-current liabilities | 1,396,000 | 1,200,000 | 1,309,000 | 1,363,000 | 1,380,000 | 1,502,000 | 1,577,000 | 3,832,000 | 3,922,000 | 4,004,000 | 4,130,000 | 3,934,000 | 3,480,000 | 3,496,000 | 3,735,000 | 3,015,000 | 765,000 | 999,000 | 450,000 | |
| total liabilities | 84,604,000 | 83,303,000 | 88,839,000 | 91,420,000 | 91,525,000 | 99,150,000 | 97,794,000 | 244,883,000 | 118,657,000 | 116,548,000 | 125,327,000 | 100,342,000 | 109,622,000 | 115,251,000 | 118,573,000 | 100,648,000 | 55,365,000 | 19,957,000 | 7,579,000 | 11,624,000 |
| commitments and contingencies - note 13 | ||||||||||||||||||||
| stockholders' equity | ||||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of june 30, 2025 and december 31, 2024 | ||||||||||||||||||||
| common stock | 3,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | |||||||
| additional paid-in capital | 900,139,000 | 681,177,000 | 677,859,000 | 674,643,000 | 664,457,000 | 591,166,000 | 587,942,000 | 511,632,000 | 406,546,000 | 404,114,000 | 402,389,000 | 357,065,000 | 352,342,000 | 336,485,000 | 331,032,000 | 325,657,000 | 320,571,000 | 316,022,000 | 312,428,000 | 310,450,000 |
| accumulated other comprehensive loss | -699,000 | -2,286,000 | -4,031,000 | -2,328,000 | -251,000 | |||||||||||||||
| accumulated deficit | -650,716,000 | -623,834,000 | -602,305,000 | -583,520,000 | -557,996,000 | -537,068,000 | -513,007,000 | -560,748,000 | -443,661,000 | -419,063,000 | -401,441,000 | -345,940,000 | -319,633,000 | -285,760,000 | -235,649,000 | -185,263,000 | -134,076,000 | -93,150,000 | -61,126,000 | -42,808,000 |
| total stockholders’ equity | 248,727,000 | 55,059,000 | 71,525,000 | 88,797,000 | 108,868,000 | 53,849,000 | 74,937,000 | 949,000 | 11,126,000 | 32,710,000 | 50,725,000 | 95,383,000 | 140,394,000 | 186,495,000 | 222,872,000 | 251,302,000 | 267,642,000 | |||
| total liabilities and stockholders' equity | 333,331,000 | 138,362,000 | 160,364,000 | 180,217,000 | 200,393,000 | 152,999,000 | 172,731,000 | 126,276,000 | 111,468,000 | 142,332,000 | 165,976,000 | 213,956,000 | 241,042,000 | 241,860,000 | 242,829,000 | 258,881,000 | 279,266,000 | |||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of march 31, 2025 and december 31, 2024 | ||||||||||||||||||||
| assets held for sale | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | ||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of december 31, 2024 and december 31, 2023 | ||||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of september 30, 2024 and december 31, 2023 | ||||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of june 30, 2024 and december 31, 2023 | ||||||||||||||||||||
| accumulated other comprehensive income | 2,405,000 | |||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of march 31, 2024 and december 31, 2023 | ||||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of december 31, 2023 and december 31, 2022 | ||||||||||||||||||||
| liabilities and stockholders' (deficit) equity | ||||||||||||||||||||
| current liabilities | ||||||||||||||||||||
| warrant liability | 140,534,000 | |||||||||||||||||||
| deferred revenue, net of current portion | 2,951,000 | 6,212,000 | ||||||||||||||||||
| stockholders' (deficit) equity | ||||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of september 30, 2023 and december 31, 2022 | ||||||||||||||||||||
| total stockholders’ (deficit) equity | -49,114,000 | -37,114,000 | -14,948,000 | |||||||||||||||||
| total liabilities and stockholders' (deficit) equity | 195,769,000 | 81,543,000 | 101,600,000 | |||||||||||||||||
| commitments and contingencies - note 12 | ||||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of june 30, 2023 and december 31, 2022 | ||||||||||||||||||||
| commitments and contingencies - note 11 | ||||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of march 31, 2023 and december 31, 2022 | ||||||||||||||||||||
| build-to-suit lease liability | 25,496,000 | 25,609,000 | 25,752,000 | 25,900,000 | 26,607,000 | 26,209,000 | ||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of december 31, 2022 and december 31, 2021 | ||||||||||||||||||||
| deferred lease asset | 630,000 | 643,000 | 655,000 | 667,000 | 691,000 | 691,000 | 703,000 | 715,000 | ||||||||||||
| commitments and contingencies - note 9 | ||||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of september 30, 2022 and december 31, 2021 | ||||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of june 30, 2022 and december 31, 2021 | ||||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of march 31, 2022 and december 31, 2021 | ||||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of december 31, 2021 and december 31, 2020 | ||||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of september 30, 2021 and december 31, 2020 | ||||||||||||||||||||
| commitments and contingencies - note 10 | ||||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of june 30, 2021 and december 31, 2020 | ||||||||||||||||||||
| deferred offering costs | 128,000 | |||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of march 31, 2021 and december 31, 2020 | ||||||||||||||||||||
| property and equipment | 287,000 | 28,000 | ||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of december 31, 2020; no shares authorized, issued and outstanding as of december 31, 2019 | ||||||||||||||||||||
| prepaid expenses | 604,000 | |||||||||||||||||||
| accrued expenses | 2,727,000 | |||||||||||||||||||
| due to related party | 60,000 | |||||||||||||||||||
| preferred stock, 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of september 30, 2020; no shares authorized, issued and outstanding as of december 31, 2019 |
We provide you with 20 years of balance sheets for Taysha Gene Therapies stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Taysha Gene Therapies. Explore the full financial landscape of Taysha Gene Therapies stock with our expertly curated balance sheets.
The information provided in this report about Taysha Gene Therapies stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.